Comparative Evaluation of an Extensive Histopathologic Examination and a Real-Time Reverse-Transcription-Polymerase Chain Reaction Assay for Mammaglobin and Cytokeratin 19 on Axillary Sentinel Lymph Nodes of Breast Carcinoma Patients
Authors:
- Giuseppe VialeGVGiuseppe Viale
- Patrizia Dell'ORtoPDPatrizia Dell'ORto
- Maria O. BiasiMBMaria O. Biasi
- Viviana StufanoVSViviana Stufano
- Luciana N. De Brito LimaLLLuciana N. De Brito Lima
- Giovanni PaganelliGPGiovanni Paganelli
- Patrick MaisonneuvePMPatrick Maisonneuve
- Janet M. VargoJVJanet M. Vargo
- George GreenGGGeorge Green
- Wuxiong CaoWCWuxiong Cao
- Ailsa SwijterASAilsa Swijter
- Giovanni MazzarolGMGiovanni Mazzarol
- 1 January 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 247 (1) , 136-142
Abstract
To assess the accuracy of a commercially available real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 mRNAs [GeneSearch Breast Lymph Node (BLN) Assay, Veridex LLC, Warren, NJ] in the detection of axillary sentinel lymph nodes (SLNs) metastases in patients with breast carcinoma. Because of the lack of standardized and widely accepted protocols for a truly accurate histopathologic examination of SLN, the relative merits of alternative assays based on the identification of tumor specific mRNA markers deserve further assessment. A prospective series of 293 consecutive SLNs from 293 patients was evaluated. The BLN assay results were compared with those of an extensive histopathologic examination of the entire SLNs performed on serial frozen sections cut at 40 to 50 μm intervals. The BLN assay correctly identified 51 of 52 macrometastatic and 5 of 20 micrometastatic SLNs, with a sensitivity of 98.1% to detect metastases larger than 2 mm, 94.7% for metastases larger than 1 mm, and 77.8% for metastases larger than 0.2 mm. The overall concordance with histopathology was 90.8%, with specificity of 95.0%, positive predictive value of 83.6%, and negative predictive value of 92.9%. When the results were evaluated according to the occurrence of additional metastases to non-SLN in patients with histologically positive SLNs, the assay was positive in 33 (91.7%) of the 36 patients with additional metastases and in 22 (66.6%) of the 33 patients without further echelon involvement. The sensitivity of the reverse-transcription -polymerase chain reaction assay is comparable to that of the histopathologic examination of the entire SLN by serial sectioning at 1.5 to 2 mm.Keywords
This publication has 27 references indexed in Scilit:
- Pathologic examination of the axillary sentinel lymph nodes in patients with early-stage breast carcinoma: current and resolving controversies on the basis of the European Institute of Oncology experienceVirchows Archiv, 2005
- Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening PathologyJournal of Clinical Pathology, 2004
- Molecular Detection of Micrometastatic Breast Cancer in Histopathology-Negative Axillary Lymph Nodes Correlates With Traditional Predictors of PrognosisAnnals of Surgery, 2004
- RT-PCR for Mammaglobin Genes,MGB1andMGB2, Identifies Breast Cancer Micrometastases in Sentinel Lymph NodesAmerican Journal of Clinical Pathology, 2004
- Quantitative evaluation of metastases in axillary lymph nodes of breast cancerBritish Journal of Cancer, 2003
- Detection of micrometastatic breast cancer by means of real time quantitative RT‐PCR and immunostaining in perioperative blood samples and sentinel nodesInternational Journal of Cancer, 2003
- Detection of micrometastases in lymph nodes from patients with breast cancerBritish Journal of Surgery, 2002
- Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodesInternational Journal of Cancer, 2001
- Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panelInternational Journal of Cancer, 2001
- Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients.Journal of Clinical Oncology, 1998